文献速递乳腺癌

瑞典SBII:2pre试验中辅助他莫昔芬治疗对绝经前雌激素受体阳性乳腺癌患者三十年无乳腺癌间期和无远处复发间期的影响

Effects of adjuvant tamoxifen over three decades on breast cancer-free and distant recurrence-free interval among premenopausal women with oestrogen receptor-positive breast cancer randomised in the Swedish SBII:2pre trial.
PubMed 文献 · Eur J Cancer · 2019-02-12

瑞典SBII:2pre试验将绝经前原发乳腺癌患者随机分配至2年他莫昔芬组(n=277)或无全身治疗组(n=287),中位随访28年。在雌激素受体阳性肿瘤患者(n=362)中,他莫昔芬延长无乳腺癌间期(HR=0.62,95%CI 0.47-0.82,p=0.001)和无远处复发间期(HR=0.73,95%CI 0.54-0.99,p=0.043),对侧乳腺癌发生率降低42%(HR=0.58,95%CI 0.35-0.96,p=0.035),但远处复发后生存期较短。

要点

  • 雌激素受体阳性患者中,2年他莫昔芬延长无乳腺癌间期(HR=0.62)和无远处复发间期(HR=0.73)。
  • 他莫昔芬组对侧乳腺癌发生率降低42%(HR=0.58,95%CI 0.35-0.96,p=0.035)。
  • 雌激素受体阳性远处复发患者中,他莫昔芬组远处复发后生存期较短(中位29个月 vs 43个月)。

核心结论

  • 经过三十年随访,2年辅助他莫昔芬降低乳腺癌相关事件和远处复发发生率, carryover效应似乎延伸超过15年。
  • 辅助他莫昔芬似乎与远处复发诊断后生存期较短相关。

研究设计与样本

  • 瑞典SBII:2pre随机对照试验,绝经前原发乳腺癌患者随机分配至2年他莫昔芬组(n=277)或无全身治疗组(n=287),不论雌激素受体状态。
  • 事件信息通过病历回顾和国家登记处收集,无事件患者中位随访28年,仅4例存活患者随访<20年。

主要发现

  • 30年随访时,意向治疗人群中他莫昔芬较无治疗延长无乳腺癌间期(HR=0.76,95%CI 0.61-0.94,p=0.011)。
  • 雌激素受体阳性肿瘤患者(n=362)中,他莫昔芬延长无乳腺癌间期(HR=0.62,95%CI 0.47-0.82,p=0.001)和无远处复发间期(HR=0.73,95%CI 0.54-0.99,p=0.043)。
  • 无乳腺癌间期的阳性效应在>15-30年 interval也显著(HR=0.53,95%CI 0.28-0.98,p=0.042)。
  • 雌激素受体阳性肿瘤且诊断远处复发的患者(n=165)中,他莫昔芬组远处复发后生存期较短(中位29个月 vs 43个月)。
  • 他莫昔芬组对侧乳腺癌发生率降低42%(HR=0.58,95%CI 0.35-0.96,p=0.035),其他第二恶性肿瘤无差异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: The primary aim was to compare 2 years of adjuvant tamoxifen versus no systemic treatment in premenopausal patients with oestrogen receptor (ER)-positive tumours, regarding breast cancer-free interval (BCFi) and distant recurrence-free interval (D-RFi), with 30 years of follow-up and for specified intervals. Moreover, we aimed to investigate the effects of adjuvant tamoxifen on the incidence of secondary malignancies and survival after distant recurrence. METHODS: Premenopausal patients with primary breast cancer were randomised to 2 years of tamoxifen (n = 277) or no systemic treatment (n = 287), irrespective of ER status. Information regarding events was collected by a review of medical records and from national registers. RESULTS: The median follow-up for all patients without events was 28 years, and only four of the patients alive had a follow-up of <20 years. With 30 years of follow-up, tamoxifen prolonged BCFi in the intention-to-treat population (hazard ratio [HR] = 0.76, 95% confidence interval (CI) 0.61-0.94, p = 0.011) compared with no treatment. In patients with ER-positive tumours (n = 362), tamoxifen prolonged BCFi (HR = 0.62, 95% CI 0.47-0.82, p = 0.001) and D-RFi (HR = 0.73, 95% CI 0.54-0.99, p = 0.043). The positive effect on BCFi was significant also for the interval >15-30 years (HR = 0.53, 95% CI 0.28-0.98, p = 0.042). For patients with ER-positive tumours who were diagnosed with distant recurrence (n = 165), survival after distant recurrence was shorter among tamoxifen-treated patients (median, 29 months versus 43 months). The incidence of contralateral breast cancer was 42% lower in the tamoxifen group (HR = 0.58, 95% CI 0.35-0.96, p = 0.035), whereas no differences were observed regarding other secondary malignancies. CONCLUSIONS: With three decades of follow-up, 2 years of adjuvant tamoxifen reduced the incidence of breast cancer-related events and distant recurrence, and the carryover effect seems to extend beyond 15 years. Moreover, adjuvant tamoxifen seems to be associated with shorter survival after diagnosis of distant recurrence.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Ekholm M, Bendahl PO, Fernö M, et al. Effects of adjuvant tamoxifen over three decades on breast cancer-free and distant recurrence-free interval among premenopausal women with oestrogen receptor-positive breast cancer randomised in the Swedish SBII:2pre trial. Eur J Cancer. 2019. PMID: 30769227. doi:10.1016/j.ejca.2018.12.034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。